Grifols, S.A. (NASDAQ:GRFS) Shares Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC boosted its position in Grifols, S.A. (NASDAQ:GRFS) by 11.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,045,260 shares of the biotechnology company’s stock after purchasing an additional 324,869 shares during the period. Janus Henderson Group PLC’s holdings in Grifols were worth $22,642,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Helikon Investments Ltd acquired a new stake in shares of Grifols during the 4th quarter valued at $580,000. Norges Bank acquired a new stake in shares of Grifols during the 4th quarter valued at $14,434,000. Barclays PLC lifted its position in shares of Grifols by 381.2% during the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company’s stock valued at $5,261,000 after acquiring an additional 469,401 shares during the last quarter. LPL Financial LLC lifted its position in shares of Grifols by 25.0% during the 4th quarter. LPL Financial LLC now owns 75,398 shares of the biotechnology company’s stock valued at $561,000 after acquiring an additional 15,067 shares during the last quarter. Finally, First Trust Advisors LP acquired a new stake in shares of Grifols during the 4th quarter valued at $75,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Morgan Stanley assumed coverage on Grifols in a research report on Wednesday, February 12th. They set an “overweight” rating for the company. StockNews.com upgraded Grifols from a “hold” rating to a “buy” rating in a report on Thursday.

Grifols Price Performance

GRFS opened at $7.85 on Friday. The stock has a fifty day moving average of $7.29 and a 200-day moving average of $7.64. The firm has a market capitalization of $5.40 billion, a P/E ratio of 6.71 and a beta of 0.44. Grifols, S.A. has a 12-month low of $5.79 and a 12-month high of $9.96. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.